ClinicalTrials.gg
RecruitingNCT06072482AVASETUpdated Nov 13, 2026

A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis

A Phase 4 interventional study of Avacopan and Placebo in Antineutrophil Cytoplasmic Antibody-associated Vasculitis, sponsored by Amgen. Recruiting at 82 sites in 7 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Amgen · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 9 months later.
Updated Nov 13, 2026Site recruiting status changedEligibility revised+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing avacopan in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis — 3 open to participants now, 3 under way, 1 of them phase 3. avacopan · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis.

Planned enrollment
2nd of 10
300 · median 69
Started
2024
with 1 other
Phase 4
2 of 10
2 open now
Registered
8th of 10
by date
Lead sponsor
8 of 10
Amgen

Among the 10 studies testing avacopan in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, this one is the 2nd largest by planned enrollment, is one of 2 that started in 2024, is one of 2 in phase 4, and was the 8th registered.

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

158 studies on the registry are indexed under Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; 76 are open to participants now.

Browse Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis studies →

Open to participants now

3 of the 10 studies testing avacopan in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About avacopan

avacopan: first FDA approval 2021 (TAVNEOS), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis studies recruiting now, 21 (38%) set no upper age limit and 28 (50%) stop at 75 or younger; 9 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing avacopan in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the long-term safety of avacopan in participants with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).

03

Conditions studied

  • Antineutrophil Cytoplasmic Antibody-associated Vasculitis

Keywords

  • Avacopan
  • ANCA-associated Vasculitis
  • AAV
04

Who can participate

The criteria were revised on the registry on Sep 30, 2026. See what changed

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants has provided before initiation of any study-specific activities/procedures.
  • Newly diagnosed or relapse of granulomatosis with polyangiitis or microscopic polyangiitis, consistent with Chapel-Hill Consensus Conference definitions (Jennette et al, 2013), where induction treatment with cyclophosphamide or rituximab is needed.

Note: For participants receiving azathioprine, mycophenolate, or methotrexate, these medications must be discontinued prior to initiation of induction treatment. Participants receiving, or planned to receive combined rituximab and cyclophosphamide for remission induction of the current disease episode at the time of enrollment are not eligible.

  • Age >/= 18 years (or >/= legal age within the country if it is older than 18 years).
  • Positive test for anti-positive antiproteinase 3 or antimyeloperoxidase (current or historic) antibodies.
  • At least 1 Birmingham Vasculitis Activity Score (BVAS) major item, or at least 3 BVAS nonmajor items, or at least the 2 renal items of proteinuria and hematuria.
  • >/= 15 mL/min/1.73 m\^2 (using Chronic Kidney Disease Epidemiology Collaboration equations).

Exclusion criteria

Exclusion Criteria:

  • Alveolar hemorrhage requiring invasive pulmonary ventilation support anticipated to last beyond the screening period of the study.
  • Any other known multisystem disease that may confound study assessments and study conclusions including but not limited to eosinophilic granulomatosis with polyangiitis (GPA [Churg-Strauss]), systemic lupus erythematosus, immunoglobulin (Ig) A vasculitis (Henoch-Schönlein), rheumatoid vasculitis, Sjogren's syndrome, anti-glomerular basement membrane disease, or cryoglobulinemic vasculitis.
  • Any other medical condition requiring or expected to require continued use of therapies, including that may cause confoundment with study assessments and study conclusions.
  • Received dialysis or plasma exchange within 16 weeks before Day 1 randomization.
  • Have had a kidney transplant.
  • (except curatively treated nonmelanoma skin cancers, curatively treated cervical carcinoma in situ, or breast ductal carcinoma in situ) within the last 5 years before Day 1 randomization.
  • Acute or chronic, active virus or virus, or infection during screening.
  • Any known exposure to a case of active tuberculosis (TB) within the last 12 weeks before Day 1 randomization.
  • Positive test for active or latent TB during screening.
  • White blood cell count \< 3500/µL, \< 1500/µL, or lymphocyte count \< 500/µl. Note: Complete Blood Count can be repeated once in the screening period at the investigator discretion. In such instances, eligibility will be determined based on the repeat complete blood count.
  • Evidence of hepatic disease including prior diagnosis of cirrhosis.
  • (AST), alanine aminotransferase (ALT), or alkaline phosphatase (ALP) >2.0 times the (ULN).
  • Total > 1.5 times the ULN. Note: A participant with documented Gilbert's syndrome with total bilirubin \< 2 x ULN may be eligible.
  • Any of the following within 6 weeks prior to Day 1 randomization: serious infection, infection requiring treatment with intravenous (IV) anti-infective agents, any other infection (including active infection, chronic infection, opportunistic infection, or history of recurrent infection) that in the opinion of the investigator would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion. Oral or vaginal candidiasis and cutaneous or nail fungal infections that are not serious do not constitute an exclusion.
  • Any of the following within 12 weeks prior to Day 1 randomization: myocardial infarction, stroke, unstable angina, symptomatic congestive heart failure requiring prescription medication, any other clinically significant cardiovascular disease that in the opinion of the investigator would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion.
  • Received cyclophosphamide (CYC) within 12 weeks before signing the ; if on azathioprine (AZA), mycophenolate, or methotrexate (MTX) at the time of screening, these drugs must be withdrawn before receiving CYC. Note: If induction therapy with CYC was started within 2 weeks before signing the informed consent for the current episode of newly diagnosed or relapse of GPA or microscopic polyangiitis (MPA), the participant may be eligible, provided no CYC was received within 12 weeks before the start of the current induction therapy and if on AZA, mycophenolate, or MTX, these were withdrawn prior to receiving the current induction therapy with CYC.
  • Have been taking an oral daily dose of a glucocorticoid of more than 10 mg prednisone equivalent for more than 6 weeks continuously before signing of the informed consent.
  • Received RTX or other B-cell depleting therapies within 26 weeks before signing of the informed consent; if on AZA, mycophenolate, or MTX at the time of screening, these drugs must be withdrawn before receiving rituximab (RTX). Note: If induction therapy with RTX was started within 2 weeks before signing the informed consent for the current episode of newly diagnosed or relapse of GPA or MPA, the participant may be eligible, provided no RTX was received within 26 weeks before the start of the current induction therapy and if on AZA, mycophenolate, or MTX, these were withdrawn prior to receiving the current induction therapy with RTX.
  • Received any of the following within 16 weeks before Day 1 randomization:
  • antitumor necrosis factor treatment
  • abatacept
  • alemtuzumab
  • IV Ig
  • belimumab
  • anti interleukin-6 agent (eg, tocilizumab, sarilumab).
  • Taking a strong or moderate inducer of the cytochrome P450 3A4 () enzyme unless the strong or moderate CYP3A4 inducer can be changed to an alternative medicine at least 1 week before Day 1 randomization.
  • Received an drug within 30 days or within 5 half-lives (whichever is longer) before Day 1 randomization.
  • Previously received avacopan without clinical benefit per the Investigator's opinion or received avacopan within 60 days before Day 1 randomization.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Group A: Avacopan + Standard of Care (SoC)

    Avacopan 30 mg twice daily for 5 years + SoC background immunosuppressive therapy.

    Drug: Avacopan · Drug: Standard of Care

  • Experimental
    Group B: Avacopan/Placebo + SoC

    Avacopan 30 mg twice daily for 1 year, followed by placebo twice daily for 4 years + SoC background immunosuppressive therapy.

    Drug: Avacopan · Drug: Placebo · Drug: Standard of Care

  • Placebo comparator
    Group C: Placebo + SoC

    Placebo twice daily for 5 years + SoC background immunosuppressive therapy.

    Drug: Placebo · Drug: Standard of Care

Interventions

  • Administered orally.

    Also known as: CCX168

  • DrugPlacebo

    Administered orally.

  • DrugStandard of Care

    All participants will receive SoC background immunosuppressive therapy for induction and maintenance, at the discretion of the Investigator and as supported by current guidelines, product labels and local practices and informed by the individual participant's clinical condition, preferences, and values.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)

    Time frame: Up to Month 60

  2. Percentage of Participants Experiencing Adverse Events of Special Interest

    Time frame: Up to Month 60

  3. Percentage of Participants Experiencing Serious Adverse Events

    Time frame: Up to Month 60

  4. Percentage of Participants Experiencing Adverse Events Leading to Withdrawal

    Time frame: Up to Month 60

  5. Percentage of Participants Experiencing Adverse Events Leading to Death

    Time frame: Up to Month 60

  6. Number of Participants Experiencing Clinical Significant Changes from Baseline in Vital Signs Measurements

    Time frame: Up to Month 60

  7. Number of Participants Experiencing Clinical Significant Changes from Baseline in Hematology Assessments

    Time frame: Up to Month 60

  8. Number of Participants Experiencing Clinical Significant Changes from Baseline in Serum Chemistry Assessments

    Time frame: Up to Month 60

  9. Number of Participants Experiencing Clinical Significant Changes from Baseline in Urinalysis Assessments

    Time frame: Up to Month 60

Secondary outcomes

  1. Group A and B Participants who Achieved Remission at Month 12: Time to Relapse in AAV Between Month 12 and Month 60

    Time frame: Month 12 to Month 60

  2. Group A and B Participants who Achieved Remission at Month 12: Percentage of Participants who Relapse After Achieving Remission at Month 12

    Time frame: Month 12 to Month 60

  3. Groups A and C: Percentage of Participants who Achieved Sustained Remission at Month 60

    Time frame: Month 60

  4. Group A and C Participants with Overt Renal Disease at Baseline: Change from Baseline to Month 60 in Estimated Glomerular Filtration Rate (eGFR)

    Time frame: Baseline and Month 60

  5. Groups A and C: Change from Baseline to Month 60 in Short Form 36 Health Survey Version 2 (SF-36 v2) General Health Perception Score

    Time frame: Baseline and Month 60

  6. Groups A and C: Change from Baseline to Month 60 in EuroQoL-5 Dimension 5 Levels (EQ-5D-5L) Visual Analogue Scale (VAS)

    Time frame: Baseline and Month 60

  7. Percentage of Participants who Achieved Remission at Month 6

    Time frame: Month 6

  8. Groups A and C: Change from Baseline to Month 60 in Vasculitis Damage Index (VDI)

    Time frame: Baseline and Month 60

  9. Groups A and C: Percentage of Participants with Composite Outcome of Initiation of Maintenance Dialysis, Kidney Transplantation, or Death

    Time frame: Up to Month 60

  10. Percentage of Participants With Glucocorticoid Use

    Time frame: Up to Month 60

  11. Percentage of Participants With Immunosuppressant Use

    Time frame: Up to Month 60

07

Study locations

76 of 82 sites recruiting
  • Orthopedic Physicians Alaska
    Anchorage, Alaska 99508, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Scottsdale Healthcare at Shea - HonorHealth
    Scottsdale, Arizona 85258, United States
    Recruiting
  • Southwest Kidney Institute
    Surprise, Arizona 85374, United States
    Recruiting
  • Unity Health
    Searcy, Arkansas 72143, United States
    Recruiting
  • Medvin Clinical Research
    Covina, California 91722, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Palo Alto Medical Foundation Fremont
    Fremont, California 94538, United States
    Recruiting
  • The Nephrology Group
    Fresno, California 93720, United States
    Recruiting
  • Providence Medical Foundation
    Fullerton, California 92835, United States
    Recruiting
  • Southland Arthritis and Osteoarthritis Medical Center, Inc
    Menifee, California 92586, United States
    Recruiting
  • University of California San Francisco- Zuckerburg San Francisco General
    San Francisco, California 94110, United States
    Recruiting
  • Harbor University of California at Los Angeles Medical Center
    Torrance, California 90502, United States
    Recruiting
  • Amicis Research Center
    Valencia, California 91355, United States
    Recruiting
  • University of Colorado
    Aurora, Colorado 80045, United States
    Recruiting
  • Florida Kidney Physicians
    Boca Raton, Florida 33487, United States
    Recruiting
  • Malcom Randall Veterans Affairs Medical Center
    Gainesville, Florida 32608, United States
    Recruiting
  • Mayo Clinic
    Jacksonville, Florida 32224, United States
    Recruiting
  • ClinTrial Research Oakwater, Llc
    Orlando, Florida 32806, United States
    Recruiting
  • University of South Florida
    Tampa, Florida 33606, United States
    Recruiting
  • Emory University
    Atlanta, Georgia 30322, United States
    Recruiting
  • Lake Cumberland Rheumatology
    New Albany, Indiana 47150, United States
    Recruiting
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
    Recruiting
  • University of Kentucky
    Lexington, Kentucky 40536, United States
    Recruiting
  • Johns Hopkins Bayview Medical Center
    Baltimore, Maryland 21202, United States
    Recruiting
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
    Recruiting
  • Brigham and Womens Hospital
    Boston, Massachusetts 02115, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Henry Ford Health System
    Detroit, Michigan 48202, United States
    Recruiting
  • Kidney Michigan Institute
    Saginaw, Michigan 49804, United States
    Recruiting
  • Clinical Research Institute of Michigan
    Saint Clair Shores, Michigan 48081, United States
    Recruiting
  • Revive Research Institute
    Sterling Heights, Michigan 48313, United States
    Recruiting
  • University of Minnesota
    Minneapolis, Minnesota 55414, United States
    Recruiting
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
    Recruiting
  • Renown Rheumatology
    Reno, Nevada 89502, United States
    Recruiting
  • Dartmouth Hitchcock Medical Center
    Lebanon, New Hampshire 03766, United States
    Recruiting
  • Renal Medicine Associates
    Albuquerque, New Mexico 87109, United States
    Recruiting
  • New York Nephrology Vasculitis and Glomerular Center
    Albany, New York 12209, United States
    Recruiting
  • Northwell Health
    Great Neck, New York 11021, United States
    Recruiting
  • Hospital For Special Surgery
    New York, New York 10021, United States
    Recruiting
  • Carolina Kidney Associates
    Greensboro, North Carolina 27405, United States
    Recruiting
  • East Carolina University Brody Outpatient Center
    Greenville, North Carolina 27834, United States
    Recruiting
  • Brookview Hills Research Associates Llc
    Winston-Salem, North Carolina 27103, United States
    Recruiting
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
    Recruiting
  • The Ohio State University
    Columbus, Ohio 43201, United States
    Recruiting
  • Stat Research
    Miamisburg, Ohio 45342, United States
    Recruiting
  • Hightower Clinical
    Oklahoma City, Oklahoma 73114, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Oregon Health and Science University
    Portland, Oregon 97239, United States
    Recruiting
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
    Recruiting
  • Allegheny Health Network Cancer Institute at Mellon Pavilion
    Pittsburgh, Pennsylvania 15224, United States
    Recruiting
  • Nephrology Associates Inc
    East Providence, Rhode Island 02914, United States
    Recruiting
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
    Recruiting
  • Carolina Nephrology PA
    Greenville, South Carolina 29605, United States
    Recruiting
  • Dunes Clinical Research LLC
    Dakota Dunes, South Dakota 57049, United States
    Recruiting
  • West Tennessee Research Institute
    Jackson, Tennessee 38305, United States
    Recruiting
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Vital Rheumatology
    Austin, Texas 78727, United States
    Recruiting
  • Renal Disease Research Institute - Landry Office
    Dallas, Texas 75204, United States
    Recruiting
  • Epic Medical Research - Red Oak
    Dallas, Texas 75246, United States
    Recruiting
  • Texas Arthritis Center PA
    El Paso, Texas 79902, United States
    Recruiting
  • Scott and White Memorial Hospital
    Temple, Texas 76502, United States
    Recruiting
  • Nephrology Associates of Northern Virginia Inc
    Fairfax, Virginia 22033, United States
    Recruiting
  • Virginia Mason Medical Center
    Seattle, Washington 98101, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Rheumatology and Pulmonary Clinic
    Beckley, West Virginia 25801, United States
    Recruiting
  • Fakultni nemocnice Hradec Kralove
    Hradec Králové, 500 05, Czechia
    Recruiting
  • Fakultni nemocnice Olomouc
    Olomouc, 779 00, Czechia
    Recruiting
  • Fakultni nemocnice Ostrava
    Ostrava - Poruba, 708 52, Czechia
    Recruiting
  • Fakultni nemocnice Plzen
    Pilsen, 304 60, Czechia
    Recruiting
  • Fakultni nemocnice Kralovske Vinohrady
    Prague, 100 34, Czechia
    Recruiting
  • Revmatologicky ustav
    Prague, 128 00, Czechia
    Recruiting
  • Vseobecna fakultni nemocnice v Praze
    Prague, 128 08, Czechia
    Recruiting
  • Rigshospitalet
    Copenhagen, 2100, Denmark
    Recruiting
  • Odense Universitetshospital
    Odense C, 5000, Denmark
    Recruiting
  • General Hospital of Athens Laiko
    Athens, 11527, Greece
    Recruiting
  • Hippokration General Hospital of Athens
    Athens, 11527, Greece
    Recruiting
  • Debreceni Egyetem Klinikai Kozpont
    Debrecen, 4032, Hungary
    Recruiting
  • Pecsi Tudomanyegyetem Klinikai Kozpont
    Pécs, 7632, Hungary
    Recruiting
  • SPZOZ Uniwersytecki Szpital Kliniczny nr 1 im Norberta Barlickiego Uniwersytetu Medycznego w Lodzi
    Lodz, 90-153, Poland
    Recruiting
  • Spzoz Centralny Szpital Kliniczny Umed w Lodzi
    Lodz, 92-213, Poland
    Recruiting
  • Narodowy Instytut Geriatrii Reumatologii i Rehabilitacji im prof dr hab med Eleonory Reicher
    Warsaw, 02-637, Poland
    Recruiting
  • Wojskowy Instytut Medyczny - Panstwowy Instytut Badawczy Centralny Szpital Kliniczny Mon
    Warsaw, 04-141, Poland
    Recruiting
  • Spitalul Clinic Sf Maria, Bucuresti
    Bucharest, 011172, Romania
    Recruiting
  • Spitalul Clinic Dr Ion Cantacuzino
    Bucharest, 020475, Romania
    Recruiting
  • Spitalul Clinic Judetean de Urgenta Cluj
    Cluj-Napoca, 400006, Romania
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2024 (actual). Primary completion is estimated for Dec 2036, 154 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2023
First posted
Oct 10, 2023
StartActual
Feb 7, 2024
Primary completionEst.
Dec 31, 2036
CompletionEst.
Dec 31, 2036
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added, 5 sites removed. 23 sites changed recruiting status (21 now recruiting, 2 now terminated)
Show 23 sites
  • Fakultni nemocnice Hradec Kralove · Hradec Králové, CzechiaActive, not recruiting→Recruiting
  • Fakultni nemocnice Olomouc · Olomouc, CzechiaActive, not recruiting→Recruiting
  • Fakultni nemocnice Ostrava · Ostrava - Poruba, CzechiaActive, not recruiting→Recruiting
  • Fakultni nemocnice Plzen · Pilsen, CzechiaActive, not recruiting→Recruiting
  • Fakultni nemocnice Kralovske Vinohrady · Prague, CzechiaActive, not recruiting→Recruiting
  • Revmatologicky ustav · Prague, CzechiaActive, not recruiting→Recruiting
  • Vseobecna fakultni nemocnice v Praze · Prague, CzechiaActive, not recruiting→Recruiting
  • Aalborg Universitetshospital · Aalborg, DenmarkActive, not recruiting→Recruiting
  • Rigshospitalet · Copenhagen, DenmarkActive, not recruiting→Recruiting
  • Odense Universitetshospital · Odense C, DenmarkActive, not recruiting→Recruiting
  • General Hospital of Athens Laiko · Athens, GreeceActive, not recruiting→Recruiting
  • Hippokration General Hospital of Athens · Athens, GreeceActive, not recruiting→Recruiting
  • Debreceni Egyetem Klinikai Kozpont · Debrecen, HungaryActive, not recruiting→Recruiting
  • Pecsi Tudomanyegyetem Klinikai Kozpont · Pécs, HungaryActive, not recruiting→Recruiting
  • SPZOZ Uniwersytecki Szpital Kliniczny nr 1 im Norberta Barlickiego Uniwersytetu Medycznego w Lodzi · Lodz, PolandActive, not recruiting→Recruiting
  • Spzoz Centralny Szpital Kliniczny Umed w Lodzi · Lodz, PolandActive, not recruiting→Recruiting
  • Narodowy Instytut Geriatrii Reumatologii i Rehabilitacji im prof dr hab med Eleonory Reicher · Warsaw, PolandActive, not recruiting→Recruiting
  • Wojskowy Instytut Medyczny - Panstwowy Instytut Badawczy Centralny Szpital Kliniczny Mon · Warsaw, PolandActive, not recruiting→Recruiting
  • Spitalul Clinic Sf Maria, Bucuresti · Bucharest, RomaniaActive, not recruiting→Recruiting
  • Spitalul Clinic Dr Ion Cantacuzino · Bucharest, RomaniaActive, not recruiting→Recruiting
  • Spitalul Clinic Judetean de Urgenta Cluj · Cluj-Napoca, RomaniaActive, not recruiting→Recruiting
  • Brigham and Womens Hospital · Boston, United StatesRecruiting→Terminated
  • Hightower Clinical · Oklahoma City, United StatesRecruiting→Terminated
Show 4 added (4 United States)
  • Carolina Nephrology PA · Greenville, United States
  • Dunes Clinical Research LLC · Dakota Dunes, United States
  • Epic Medical Research - Red Oak · Dallas, United States
  • Texas Arthritis Center PA · El Paso, United States
Show 5 removed
  • Dunes Clinical Research LLC · Sioux City, United States
  • Carolina Nephrology PA · Spartanburg, United States
  • Epic Medical Research - Red Oak · Red Oak, United States
  • Medical College of Wisconsin · Milwaukee, United States
  • Aalborg Universitetshospital · Aalborg, Denmark
across 2 updates, Sep 30, 2026 – Nov 13, 2026
Eligibility
1 inclusion criterion added; 3 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • AddedNote: For participants receiving azathioprine, mycophenolate, or methotrexate, these medications must be discontinued prior to initiation of induction treatment. Participants receiving, or planned to receive combined rituximab and cyclophosphamide for remission induction of the current disease episode at the time of enrollment are not eligible.
Exclusion criteria
  • EditedAny of the following within 6 weeks prior to Day 1 randomization: serious infection, infection requiring treatment with intravenous (IV) anti-infective agents, any other infection (including active infection, chronic infection, opportunistic infection, or history of recurrent infection) that in the opinion of the investigator would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion. Oral or vaginal candidiasis and cutaneous or nail fungal infections that are not serious do not constitute an exclusion.
  • EditedReceived cyclophosphamide (CYC) within 12 weeks before signing the informed consent; if on azathioprine (AZA), mycophenolate, or methotrexate (MTX) at the time of screening, these drugs must be withdrawn before receiving CYC. Note: If induction therapy with CYC was started within 1 week2 weeks before signing the informed consent for the current episode of newly diagnosed or relapse of GPA or microscopic polyangiitis (MPA), the participant may be eligible, provided no CYC was received within 12 weeks before the start of the current induction therapy and if on AZA, mycophenolate, or MTX, these were withdrawn prior to receiving the current induction therapy with CYC.
  • EditedReceived RTX or other B-cell depleting therapies within 26 weeks before signing of the informed consent; if on AZA, mycophenolate, or MTX at the time of screening, these drugs must be withdrawn before receiving rituximab (RTX). Note: If induction therapy with RTX was started within 1 week2 weeks before signing the informed consent for the current episode of newly diagnosed or relapse of GPA or MPA, the participant may be eligible, provided no RTX was received within 26 weeks before the start of the current induction therapy and if on AZA, mycophenolate, or MTX, these were withdrawn prior to receiving the current induction therapy with RTX.
Sep 30, 2026
Show all 2 updates
  1. Nov 13, 2026
    4 sites added, 5 sites removed. 2 sites changed recruiting status (2 now terminated)
    Show 2 sites
    • Brigham and Womens Hospital · Boston, United StatesRecruiting→Terminated
    • Hightower Clinical · Oklahoma City, United StatesRecruiting→Terminated
    Show 4 added (4 United States)
    • Carolina Nephrology PA · Greenville, United States
    • Dunes Clinical Research LLC · Dakota Dunes, United States
    • Epic Medical Research - Red Oak · Dallas, United States
    • Texas Arthritis Center PA · El Paso, United States
    Show 5 removed
    • Dunes Clinical Research LLC · Sioux City, United States
    • Carolina Nephrology PA · Spartanburg, United States
    • Epic Medical Research - Red Oak · Red Oak, United States
    • Medical College of Wisconsin · Milwaukee, United States
    • Aalborg Universitetshospital · Aalborg, Denmark
    + 1 other change: verification date
  2. Sep 30, 2026
    21 sites changed recruiting status (21 now recruiting)
    Show 21 sites
    • Fakultni nemocnice Hradec Kralove · Hradec Králové, CzechiaActive, not recruiting→Recruiting
    • Fakultni nemocnice Olomouc · Olomouc, CzechiaActive, not recruiting→Recruiting
    • Fakultni nemocnice Ostrava · Ostrava - Poruba, CzechiaActive, not recruiting→Recruiting
    • Fakultni nemocnice Plzen · Pilsen, CzechiaActive, not recruiting→Recruiting
    • Fakultni nemocnice Kralovske Vinohrady · Prague, CzechiaActive, not recruiting→Recruiting
    • Revmatologicky ustav · Prague, CzechiaActive, not recruiting→Recruiting
    • Vseobecna fakultni nemocnice v Praze · Prague, CzechiaActive, not recruiting→Recruiting
    • Aalborg Universitetshospital · Aalborg, DenmarkActive, not recruiting→Recruiting
    • Rigshospitalet · Copenhagen, DenmarkActive, not recruiting→Recruiting
    • Odense Universitetshospital · Odense C, DenmarkActive, not recruiting→Recruiting
    • General Hospital of Athens Laiko · Athens, GreeceActive, not recruiting→Recruiting
    • Hippokration General Hospital of Athens · Athens, GreeceActive, not recruiting→Recruiting
    • Debreceni Egyetem Klinikai Kozpont · Debrecen, HungaryActive, not recruiting→Recruiting
    • Pecsi Tudomanyegyetem Klinikai Kozpont · Pécs, HungaryActive, not recruiting→Recruiting
    • SPZOZ Uniwersytecki Szpital Kliniczny nr 1 im Norberta Barlickiego Uniwersytetu Medycznego w Lodzi · Lodz, PolandActive, not recruiting→Recruiting
    • Spzoz Centralny Szpital Kliniczny Umed w Lodzi · Lodz, PolandActive, not recruiting→Recruiting
    • Narodowy Instytut Geriatrii Reumatologii i Rehabilitacji im prof dr hab med Eleonory Reicher · Warsaw, PolandActive, not recruiting→Recruiting
    • Wojskowy Instytut Medyczny - Panstwowy Instytut Badawczy Centralny Szpital Kliniczny Mon · Warsaw, PolandActive, not recruiting→Recruiting
    • Spitalul Clinic Sf Maria, Bucuresti · Bucharest, RomaniaActive, not recruiting→Recruiting
    • Spitalul Clinic Dr Ion Cantacuzino · Bucharest, RomaniaActive, not recruiting→Recruiting
    • Spitalul Clinic Judetean de Urgenta Cluj · Cluj-Napoca, RomaniaActive, not recruiting→Recruiting
    Eligibility 1 inclusion criterion added; 3 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • AddedNote: For participants receiving azathioprine, mycophenolate, or methotrexate, these medications must be discontinued prior to initiation of induction treatment. Participants receiving, or planned to receive combined rituximab and cyclophosphamide for remission induction of the current disease episode at the time of enrollment are not eligible.
    Exclusion criteria
    • EditedAny of the following within 6 weeks prior to Day 1 randomization: serious infection, infection requiring treatment with intravenous (IV) anti-infective agents, any other infection (including active infection, chronic infection, opportunistic infection, or history of recurrent infection) that in the opinion of the investigator would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion. Oral or vaginal candidiasis and cutaneous or nail fungal infections that are not serious do not constitute an exclusion.
    • EditedReceived cyclophosphamide (CYC) within 12 weeks before signing the informed consent; if on azathioprine (AZA), mycophenolate, or methotrexate (MTX) at the time of screening, these drugs must be withdrawn before receiving CYC. Note: If induction therapy with CYC was started within 1 week2 weeks before signing the informed consent for the current episode of newly diagnosed or relapse of GPA or microscopic polyangiitis (MPA), the participant may be eligible, provided no CYC was received within 12 weeks before the start of the current induction therapy and if on AZA, mycophenolate, or MTX, these were withdrawn prior to receiving the current induction therapy with CYC.
    • EditedReceived RTX or other B-cell depleting therapies within 26 weeks before signing of the informed consent; if on AZA, mycophenolate, or MTX at the time of screening, these drugs must be withdrawn before receiving rituximab (RTX). Note: If induction therapy with RTX was started within 1 week2 weeks before signing the informed consent for the current episode of newly diagnosed or relapse of GPA or MPA, the participant may be eligible, provided no RTX was received within 26 weeks before the start of the current induction therapy and if on AZA, mycophenolate, or MTX, these were withdrawn prior to receiving the current induction therapy with RTX.
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06072482
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Oct 10, 2023
Start date
Feb 7, 2024
Primary completion
Dec 31, 2036 (estimated)
Completion
Dec 31, 2036 (estimated)
Last update
Nov 13, 2026

Study contacts

Amgen Call Center
Contact
medinfo@amgen.com
866-572-6436
MD
study director · Amgen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Avacopan

Start the discussion